NewAmsterdam Pharma
Presença
NewAmsterdam Pharma é uma empresa listada sob o símbolo NAMS (NL).
Executivos
Veja o organograma con seus 22 executivos principais
Biografias mais buscadas da NewAmsterdam Pharma
- Michael Davidson, Chief Executive Officer and Director
- Nicholas Downing, Director
- Sander Van Slootweg, Director
Recentes movimentos de executivos em NewAmsterdam Pharma
- Juliette Audet antes Director, foi promovido a Chief Business Officer (Notícia publicada em 2 de abril de 2024).
- William Lewis, ingressou na Companhia como Chairman of the Board (Notícia publicada em 9 de janeiro de 2024).
- Ian Somaiya, ingressou na Companhia como Chief Financial Officer (Notícia publicada em 24 de outubro de 2023).
Criar um alerta
para seguir os movimentos de executivos da NewAmsterdam Pharma.
Farmacêutica
NewAmsterdam Pharma possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de NewAmsterdam Pharma
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease | NewAmsterdam Pharma Company
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients | NewAmsterdam Pharma Company N.V.
- View more press releases Close
Redes sociais sobre NewAmsterdam Pharma
- NewAmsterdam Pharma na Wikipedia, Google News e Yahoo Finance
- NewAmsterdam Pharma na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Michael Davidson 
Ligue para a NewAmsterdam Pharma em +31 35...
